Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Miraki Innovation Launches $175 Million Fund to Solve the World’s Biggest Healthcare Problems

Miraki Innovation’s Medical Technology Breakthrough Fund Accelerates Founder’s Trajectory of Building Disruptive, Lifechanging Healthcare Companies

Founder of Miraki Innovation and co-founder of Auris Health, Christopher Velis, announced the launch of his third fund to finance and build the next generation of pioneering medical technology (medtech) companies. The $175 million Medical Technology Breakthrough Fund will support Miraki’s mission of pinpointing and solving the world’s most pressing health challenges through technology. Adhering to a proven method developed over decades of experience advising and founding companies, the team at Miraki will use capital from the fund to build and support portfolio companies, leveraging existing and new academic and research relationships to develop and commercialize novel, market-leading medtech.

Read More: Aptiv/Audi Receives Innovation Partnership Award for Automated Driving Satellite Compute Platform

The company’s unique and efficient approach to investing creates an exclusive process that has led to the successful creations and exits of more than 16 industry-leading companies. Through this repeatable process, Miraki translates ideas and research out of labs and builds them into flourishing medtech companies. Miraki works with the world’s leading institutions to license cutting-edge IP and operates its portfolio companies exclusively in its Cambridge, MassachusettsVenture Development Center. The portfolio companies will benefit from an environment rich with industry-leading experience and tools, and ongoing cost savings resulting from shared resources. The diverse skill set of the Miraki team includes experience in oncology, tissue regeneration, infectious disease, imaging and diagnostics, cardiology, trauma and robotic surgery.

Related Posts
1 of 33,429

Read More: Drones Officially Allowed to Deliver a Variety of Items in Australia’s Canberra

“With global concerns like growing antibiotic resistance that continue to strain healthcare resources, it’s more critical than ever that we advance medtech investment to bring more cutting-edge research to patients,” said Velis. “Our methodology builds and brings companies to market quickly and efficiently. By taking quantum leaps – not by making incremental improvements – we intend to bring returns to investors, while improving and saving lives.”

Miraki’s Medical Technology Breakthrough Fund will be the third fund started and managed by Velis. One of Velis’ past successes is Auris Health, a surgical robotics company that was acquired by Johnson & Johnson in February 2019 for $5.75 billion (inclusive of milestone payments), the largest venture funded medtech transaction in history.

Read More: Fly like a Hero with the Brand New Tello Iron Man Edition

Leave A Reply

Your email address will not be published.